Trial Profile
A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Emibetuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Balise
- Sponsors Eli Lilly and Company
- 05 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 02 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.